Madrigal Pharmaceuticals Inc (MDGL)
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for metabolic dysfunction-associated steatohepatitis, or MASH, in the United States. The company’s lead product is Rezdiffra, a liver-directed thyroid hormone receptor beta agonist approved for the treatment of MASH. Madrigal Pharmaceuticals was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania. Its common stock trades on the NASDAQ under the ticker MDGL.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MDGL
|
$660.41
|
24.2% Upside
|
Undervalued
|
$678.06
|
27.6% Upside
|
Undervalued
|
Good
|
0.0%
|
October 29, 2026
|
23.6x
|
9.6x
|
12.28 B
|
11.856 B
|
2.7%
|
59.4%
|
8.7
|
63.5%
|
